Nomograms predicting prognosis of patients with pathological stages T1N2-3 and T3N0 gastric cancer

Figure 4 Nomogram models for predicting the survival of patients with pT1N2-3 and pT3N0 GC. A: Nomogram model predicting the 3- and 5-year survival of patients with pT1N2-3 GC; B: Receiver operating characteristic curve (ROC) of the nomogram model for predicting the 3-year survival of patients with pT1N2-3 GC; C: ROC of the nomogram model for predicting the 5-year survival of patients with pT1N2-3 GC; D: Nomogram model for predicting the 3- and 5-year survival of patients with pT3N0 GC; E: ROC of the nomogram model for predicting the 3-year survival of patients with pT3N0 GC; F: ROC of the nomogram model for predicting the 5-year survival of patients with pT3N0 GC. CEA: Carcino-embryonic antigen; mLNR: Metastatic lymph node ratio; BMI: Body mass index.